Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $140.4 million.

  • Rocket Pharmaceuticals' Non-Current Assets fell 762.24% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $580.3 million, marking a year-over-year decrease of 1045.57%. This contributed to the annual value of $149.5 million for FY2024, which is 2052.0% down from last year.
  • Rocket Pharmaceuticals' Non-Current Assets amounted to $140.4 million in Q3 2025, which was down 762.24% from $143.8 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Non-Current Assets high stood at $188.1 million for Q4 2023, and its period low was $104.7 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $146.6 million (2025), whereas its average is $138.5 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Non-Current Assets surged by 7887.31% in 2022, and later plummeted by 2052.0% in 2024.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Non-Current Assets stood at $105.0 million in 2021, then surged by 78.87% to $187.7 million in 2022, then increased by 0.2% to $188.1 million in 2023, then decreased by 20.52% to $149.5 million in 2024, then dropped by 6.13% to $140.4 million in 2025.
  • Its last three reported values are $140.4 million in Q3 2025, $143.8 million for Q2 2025, and $146.6 million during Q1 2025.